Lomudal

Primær information

  • Handelsnavn:
  • Lomudal 20 mg/ml øjendråber, opløsning, enkeltdosisbeholder
  • Dosering:
  • 20 mg/ml
  • Lægemiddelform:
  • øjendråber, opløsning, enkeltdosisbeholder
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Allopatiske stof

Dokumenter

Lokation

  • Fås i:
  • Lomudal 20 mg/ml øjendråber, opløsning, enkeltdosisbeholder
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Lægemiddelstyrelsen - Danish Medicines Agency
  • Autorisation status:
  • Markedsført
  • Autorisationsnummer:
  • 38011
  • Sidste ændring:
  • 17-07-2018

Indlægsseddel

HOLOPACK Verpackungstechnik GmbH:

2009-02-07rf

Proof No. 2

Product:

Leaflet for Lomudal 20 mg DK

Item

Material:

Pharmapaper 50 g/m²

Holopack-Item:

B080008

Size:

150 x 250 mm, foldet to: 150 x 52,5 mm

INDLÆGSSEDDEL:

INFORMATION TIL BRUGEREN

Lomudal 20 mg/ml, øjendråber,

enkeltdosisbeholder

Natriumcromoglicat

Læs denne indlægsseddel grundigt. Den indeholder

vigtige informationer.

Du kan få Lomudal uden recept. For at opnå den bedste

behandling skal du være omhyggelig med at følge

anvisningerne for Lomudal.

Gem indlægssedlen. Du kan få brug for at læse

den igen.

Spørg på apoteket, hvis der er mere, du vil vide.

Kontakt lægen, hvis du får det værre, eller hvis

du ikke får det bedre

Tal med lægen eller apoteket, hvis en bivirkning

bliver værre, eller du får bivirkninger, som

Oversigt over indlægssedlen

Virkning og anvendelse

Det skal du vide, før du begynder at bruge

Lomudal

Sådan skal du bruge Lomudal

Bivirkninger

Opbevaring

Yderligere oplysninger

1. VIRKNING OG ANVENDELSE

Lomudal indeholder et stof (antihistamin), der lindrer

symptomer på overfølsomhed (allergi) i øjnene.

Du kan bruge Lomudal øjendråber til behandling af

Allergisk øjenbetændelse.

Betændelse i øjets bindehinde og hornhinde.

Betændelse i øjet med små sår i øjets

hornhinde.

Hvis din læge har sagt, at du skal bruge Lomudal for

noget andet, skal du altid følge lægens anvisning.

Vær opmærksom på, at betændelse i øjets hornhinde

kan være alvorligt. Tal med lægen.

2. DET SKAL DU VIDE, FØR DU

BEGYNDER AT BRUGE LOMUDAL

Brug ikke Lomudal, hvis du

er overfølsom (allergisk) over for

natriumcromoglicat eller et af de øvrige

indholdsstoffer.

Brug af anden medicin

Fortæl det altid til lægen eller apoteket, hvis du bruger

anden medicin eller har brugt det for nylig. Dette gælder

også medicin, som ikke er købt på recept, medicin

købt i udlandet, naturlægemidler, stærke vitaminer og

mineraler samt kosttilskud.

Hvis du bruger mere end ét øjenpræparat, så vent mindst

5 minutter mellem drypning med Lomudal og det andet

præparat.

Graviditet og amning

Spørg din læge eller apoteket til råds, før du bruger

nogen form for medicin.

Graviditet

Du kan bruge Lomudal under graviditet.

Amning

Du kan bruge Lomudal, selvom du ammer.

Trafik- og arbejdssikkerhed

Lomudal kan give sløret syn lige efter drypning.

Vent med at køre bil eller andet køretøj samt betjene

maskiner, indtil dit syn er klart igen.

3. SÅDAN SKAL DU BRUGE

LOMUDAL

Hvis din læge har ordineret Lomudal til dig, skal du

altid følge lægens anvisning. Er du i tvivl, så spørg

lægen eller på apoteket.

Den sædvanlige dosis er

Voksne og børn over 7 år: 1 dråbe i hvert øje 4 gange

daglig.

Børn under 7 år

GI_Lomudal_20mg_DK_R01_K02.indd 1

2009-02-07 13:35:52

HOLOPACK Verpackungstechnik GmbH:

2009-02-07rf

Proof No. 2

Product:

Leaflet for Lomudal 20 mg DK

Item

Material:

Pharmapaper 50 g/m²

Holopack-Item:

B080008

Size:

150 x 250 mm, foldet to: 150 x 52,5 mm

Du må kun bruge Lomudal til børn under 7 år efter

aftale med lægen.

Brugeranvisning

Træk det nederste øjenlåg lidt ned, og dryp en dråbe i

mellemrummet mellem øjet og øjenlåget.

Pas på at spidsen af flasken ikke rører øjet.

Slip øjenlåget og blink nogle gange, så dråben fordeles

over hele øjet.

Gentag dette i det andet øje.

Hvis du har brugt for meget Lomudal

Kontakt lægen, skadestuen eller apoteket, hvis du har

brugt mere Lomudal, end der står her, eller mere end

lægen har foreskrevet, og du føler dig utilpas.

Hvis du har glemt at bruge Lomudal

Brug aldrig dobbelt dosis, hvis du har glemt at bruge en

dosis. Fortsæt blot med den sædvanlige dosis.

4. BIVIRKNINGER

Lomudal kan som al anden medicin give bivirkninger,

men ikke alle får bivirkninger.

Almindelige til meget almindelige bivirkninger

(forekommer hos mere end 1 ud af 10 patienter)

Forbigående svien.

Lokal irritation i øjet.

Meget sjældne bivirkninger

(forekommer hos færre

end 1 ud af 10.000 patienter)

Overfølsomhedsreaktioner.

Hyppigheden er ikke kendt

Brændende eller stikkende følelse efter

drypning af øjet.

Tal med lægen eller apoteket, hvis en bivirkning bliver

værre, eller du får bivirkninger, som ikke er nævnt her.

Bivirkninger, som ikke er nævnt her, bør indberettes

til Lægemiddelstyrelsen, så viden om bivirkninger kan

blive bedre. Du eller dine pårørende kan selv indberette

bivirkninger direkte til Lægemiddelstyrelsen. Du finder

skema og vejledning på Lægemiddelstyrelsens netsted:

www.meldenbivirkning.dk.

5.

OPBEVARING

Opbevar Lomudal øjendråber utilgængeligt for børn.

Inden åbning kan du opbevare Lomudal øjendråber ved

almindelig temperatur.

Opbevar ikke en åbnet enkeltdosisbeholder.

Brug ikke Lomudal efter den udløbsdato, der står på

pakningen. Udløbsdatoen er den sidste dag i den nævnte

måned.

Aflever altid medicinrester på apoteket. Af hensyn

til miljøet må du ikke smide medicinrester i afløbet,

toilettet eller skraldespanden.

6.

YDERLIGERE OPLYSNINGER

Lomudal 20 mg/ml øjendråber indeholder:

Aktivt stof: Natriumcromoglicat.

Øvrige indholdsstoffer: Natriumchlorid, sterilt vand.

Lomudals udseende og pakningsstørrelse

Pakningsstørrelser

Lomudal øjendråber i endosisbeholdere findes i

pakninger à 20 stk. og 100 stk.

Ikke alle pakningsstørrelser er nødvendigvis

markedsført.

Indehaveren af markedsføringstilladelse og

fremstiller

Indehaver af markedsføringstilladelsen

sanofi-aventis

Denmark

A/S,

Slotsmarken

2970

Hørsholm, Danmark.

Fremstiller

Sanofi-aventis Deutschland GmbH, Frankfurt, Tyskland.

Denne indlægsseddel blev sidst revideret december 2008

GI_Lomudal_20mg_DK_R01_K02.indd 2

2009-02-07 13:35:53

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

9-11-2018

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Safety assessment of the active substance polyacrylic acid, sodium salt, cross‐linked, for use in active food contact materials

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The EFSA Panel on Food Contact Materials, Enzymes and Processing Aids (CEP) assessed the safety of polyacrylic acid, sodium salt, cross‐linked, FCM substance No 1015, which is intended to be used as a liquid absorber in the packaging of fresh or frozen foods such as meat, poultry and seafood as well as fresh fruits and vegetables. Specific migration tests were not performed due to the high absorption of liquids by the substance. The Panel noted that if polya...

Europe - EFSA - European Food Safety Authority Publications

5-11-2018

Products containing metam-sodium: ANSES announces the withdrawal of marketing authorisations

Products containing metam-sodium: ANSES announces the withdrawal of marketing authorisations

Plant protection products containing metam-sodium are used in market gardening and horticulture to disinfect the soil. Following the substance's approval at European level, ANSES reassessed the dossiers and notified the industrial companies concerned of its intention to withdraw all marketing authorisations for metam-sodium products. ANSES is also taking this opportunity to reiterate the importance of phytopharmacovigilance and the requirement for professionals to report any adverse effects on humans or ...

France - Agence Nationale du Médicament Vétérinaire

18-9-2018

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Peer review of the pesticide risk assessment of the active substance sodium hydrogen carbonate

Published on: Fri, 14 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State Austria for the pesticide active substance sodium hydrogen carbonate are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the evaluation of the representative use of sodium hyd...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

7-9-2018

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

SCA Pharmaceuticals LLC. Issues Voluntary Nationwide Recall of Furosemide 100 mg in 0.9% Sodium Chloride due to Presence of Precipitate

, SCA Pharmaceuticals LLC (“SCA Pharma”) is voluntarily recalling 7 lots of the injectable product Furosemide 100 mg in 0.9% Sodium Chloride 100 mg bag to the consumer level. This product is being recalled for visible particulate matter believed to be furosemide precipitate.

FDA - U.S. Food and Drug Administration

31-8-2018

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA announces voluntary recall of Montelukast tablets by Camber Pharmaceuticals due to incorrect drug in bottles

FDA is warning the public about a voluntary recall of one lot of montelukast sodium tablets made by Camber Pharmaceuticals due to incorrect drug in bottles

FDA - U.S. Food and Drug Administration

29-8-2018

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

SGLT2(sodium-glucose cotransporter-2) Inhibitors for Diabetes: Drug Safety Communication - Regarding Rare Occurrences of a Serious Infection of the Genital Area

Requiring a new warning about this risk to be added to the prescribing information of all SGLT2 inhibitors and to the patient Medication Guide.

FDA - U.S. Food and Drug Administration

31-7-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling two lots of Piperacillin and Tazobactam for injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level. One vial from lot# PP0317012-A was found to contain particulate matter, identified as glass within the vial and another vial from lot# PP0317059-A was fo...

FDA - U.S. Food and Drug Administration

18-7-2018

Sodium glucose co-transporter 2 inhibitors

Sodium glucose co-transporter 2 inhibitors

Safety advisory - diabetic ketoacidosis and surgical procedures

Therapeutic Goods Administration - Australia

25-5-2018

Orphan designation:  Treprostinil sodium,  for the: Treatment of chronic thromboembolic pulmonary hypertension

Orphan designation: Treprostinil sodium, for the: Treatment of chronic thromboembolic pulmonary hypertension

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Europe - EMA - European Medicines Agency

26-9-2018

Kexxtone (Elanco GmbH)

Kexxtone (Elanco GmbH)

Kexxtone (Active substance: Monensin sodium) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6324 of Wed, 26 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2235/T/10

Europe -DG Health and Food Safety

24-9-2018

Inhixa (Techdow Europe AB)

Inhixa (Techdow Europe AB)

Inhixa (Active substance: enoxaparin sodium) - Centralised - Variation - Commission Decision (2018)6101 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4264/X/18, 26

Europe -DG Health and Food Safety

27-8-2018

Arixtra (Aspen Pharma Trading Limited)

Arixtra (Aspen Pharma Trading Limited)

Arixtra (Active substance: Fondaparinux sodium) - PSUSA - Modification - Commission Decision (2018)5708 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/403/PSUSA/1467-201712

Europe -DG Health and Food Safety

3-8-2018

Sodium oxybate

Sodium oxybate

Sodium oxybate (Active substance: Sodium oxybate) - Centralised - Art 28 - (PSUR - Commission Decision (2018)5381 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10612/201710

Europe -DG Health and Food Safety

2-8-2018

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Dr Ulrich Granzer)

EU/3/18/2043 (Active substance: Combination of carboplatin and sodium valproate) - Orphan designation - Commission Decision (2018)5275 of Thu, 02 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/036/18

Europe -DG Health and Food Safety

11-7-2018

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Merck Sharp and Dohme B.V.)

Fosavance (Active substance: Alendronate Sodium / Colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4518 of Wed, 11 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/619/T/42

Europe -DG Health and Food Safety

10-7-2018

Adrovance (Merck Sharp and Dohme B.V.)

Adrovance (Merck Sharp and Dohme B.V.)

Adrovance (Active substance: Alendronate sodium / Colecalciferol) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4477 of Tue, 10 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/759/T/39

Europe -DG Health and Food Safety

10-7-2018

Ammonaps (Swedish Orphan Biovitrum International AB)

Ammonaps (Swedish Orphan Biovitrum International AB)

Ammonaps (Active substance: Sodium phenylbutyrate) - Centralised - Yearly update - Commission Decision (2018)4483 of Tue, 10 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Withdrawn application:  Prohippur, sodium benzoate, Initial authorisation

Withdrawn application: Prohippur, sodium benzoate, Initial authorisation

Europe - EMA - European Medicines Agency

19-6-2018

Xyrem (UCB Pharma S.A.)

Xyrem (UCB Pharma S.A.)

Xyrem (Active substance: Sodium oxybate) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3912 of Tue, 19 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/593/T/74

Europe -DG Health and Food Safety

1-6-2018

Valproate

Valproate

Valproate (Active substance: medicinal products containing substances related to valproate (sodium valproate, valproic acid, valproate semisodium, valpromide, valproate magnesium)) - Community Referrals - Art 31 - Commission Decision (2018)3623 of Fri, 01 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/A-31/1454

Europe -DG Health and Food Safety

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety

21-3-2018

EU/3/16/1711 (Akcea Therapeutics UK Ltd)

EU/3/16/1711 (Akcea Therapeutics UK Ltd)

EU/3/16/1711 (Active substance: Volanesorsen sodium) - Transfer of orphan designation - Commission Decision (2018)1822 of Wed, 21 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/082/16/T/01

Europe -DG Health and Food Safety